399 related articles for article (PubMed ID: 30520168)
1. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
[TBL] [Abstract][Full Text] [Related]
2. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
[TBL] [Abstract][Full Text] [Related]
3. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
[TBL] [Abstract][Full Text] [Related]
4. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
[TBL] [Abstract][Full Text] [Related]
5. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
7. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
[TBL] [Abstract][Full Text] [Related]
8. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
Paul C; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Bang B; Griffiths CE
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):119-126. PubMed ID: 27531752
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Kircik LH; Schlesinger TE; Tanghetti E
J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
[TBL] [Abstract][Full Text] [Related]
11. Fixed-dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life.
Jalili A; Yosipovitch G
J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1(Suppl 1):20-27. PubMed ID: 33619778
[TBL] [Abstract][Full Text] [Related]
12. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
[No Abstract] [Full Text] [Related]
14. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.
Menter A; Gold LS; Koo J; Villumsen J; Rosén M; Lebwohl M
Skinmed; 2017; 15(2):119-124. PubMed ID: 28528605
[TBL] [Abstract][Full Text] [Related]
15. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
Gold LS; Hansen JB; Patel D; Veverka KA; Strober B
J Am Acad Dermatol; 2020 Jul; 83(1):131-138. PubMed ID: 32430142
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States.
Wu JJ; Veverka KA; Lu M; Armstrong AW
J Dermatolog Treat; 2019 Aug; 30(5):454-460. PubMed ID: 30307343
[No Abstract] [Full Text] [Related]
19. Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials.
Veverka KA; Hansen JB; Yaloumis M; Kircik L; Stein Gold L
J Drugs Dermatol; 2021 Aug; 20(8):822-828. PubMed ID: 34397196
[TBL] [Abstract][Full Text] [Related]
20. Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials.
Iversen L; Kurvits M; Snel-Prentø AM; Menter A
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1111-1120. PubMed ID: 32785881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
